Title: METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING SKIN DISORDERS USING BINDING AGENTS SPECIFIC FOR PSMA

Abstract: Methods and compositions for treating, preventing, or diagnosing epidermal or dermal disorders, e.g., psoriasis, are disclosed. The methods and compositions of the invention use binding agents, e.g., antibodies, specific for the extracellular domain of human prostate specific membrane antigen (PSMA).
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07K 16/00; A61K 39/395
US CL : 530/387.1, 387.3, 388.1, 388.8, 388.85, 391.1; 424/130.1, 133.1, 155.1, 156.1, 178.1, 181.1, 183.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/387.1, 387.3, 388.1, 388.8, 388.85, 391.1; 424/130.1, 133.1, 155.1, 156.1, 178.1, 181.1, 183.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>US 6,200,765 B1 (MURPHY ET AL) 13 March 2001 (13/03/01), see entire document, especially column 6, lines 25-50.</td>
<td>1-20, 23-25, 27-60</td>
</tr>
<tr>
<td>Y</td>
<td>US 6,150,508 A (MURPHY ET AL) 21 November 2000 (21/11/00), see entire document, especially column 3, lines 35-45, column 14, lines 30-40.</td>
<td>1-20, 23-25, 27-60</td>
</tr>
<tr>
<td>Y</td>
<td>US 6,168,778 B1 (JANIC ET AL) 02 January 2001 (02/01/01), see entire document, especially column 5, lines 47-52.</td>
<td>1-20, 23-25, 27-60</td>
</tr>
<tr>
<td>Y</td>
<td>US 5,416,064 A (CHARI ET AL) 16 May 1995 (16/05/95), see entire document, especially column 5-6.</td>
<td>30-32</td>
</tr>
</tbody>
</table>

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"V" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

08 April 2003 (08.04.2003)

Date of mailing of the international search report

06 JUN 2003

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet) (July 1998)
Methods and Compositions for Treating and Preventing Skin Disorders Using Binding Agents Specific for PSMA

CAPLUS, MEDLINE, CANCERLIT, BIOSIS, WEST, USPATFULL, SWISSPROT, PIR, GENESEQ, SPTREMBL
Search terms: PSMA, prostate specific membrane antigen, epidermal cell, dermal cell, skin disorder, psoriasis, E99, J415, J533, J591, SEQ ID NO:1-6, 29-34, 19-20, maytansinoid, cytotoxic conjugate, extracellular domain of PSMA, antibody, anti-PSMA